Background: Intestinal microbiome constitutes a symbiotic ecosystem that is essential for health, and changes in its composition/function cause various illnesses. Biochemical milieu shapes the structure and function of the microbiome. Recently, we found marked differences in the abundance of numerous bacterial taxa between ESRD and healthy individuals. Influx of urea and uric acid and dietary restriction of fruits and vegetables to prevent hyperkalemia alter ESRD patients' intestinal milieu. We hypothesized that relative abundances of bacteria possessing urease, uricase, and p-cresol- and indole-producing enzymes is increased, while abundance of bacteria containing enzymes converting dietary fiber to short-chain fatty acids (SCFA) is reduced in ESRD. Methods: Reference sets of bacteria containing genes of interest were compiled to family, and sets of intestinal bacterial families showing differential abundances between 12 healthy and 24 ESRD individuals enrolled in our original study were compiled. Overlap between sets was assessed using hypergeometric distribution tests. Results: Among 19 microbial families that were dominant in ESRD patients, 12 possessed urease, 5 possessed uricase, and 4 possessed indole and p-cresol-forming enzymes. Among 4 microbial families that were diminished in ESRD patients, 2 possessed butyrate-forming enzymes. Probabilities of these overlapping distributions were <0.05. Conclusions: ESRD patients exhibited significant expansion of bacterial families possessing urease, uricase, and indole and p-cresol forming enzymes, and contraction of families possessing butyrate-forming enzymes. Given the deleterious effects of indoxyl sulfate, p-cresol sulfate, and urea-derived ammonia, and beneficial actions of SCFA, these changes in intestinal microbial metabolism contribute to uremic toxicity and inflammation.

Keywords:
Chronic kidney disease, Hemodialysis, Inflammation , Uric acid, Uremic toxins, Microbiome, Malnutrition, Gastrointestinal tract
1.
Vaziri ND, Wong J, Pahl MV, et al: Chronic kidney disease alters the composition of intestinal microbial flora. Kidney Int 2013;83:308-315.
2.
Lee YT: Urea concentration in intestinal fluids in normal and uremic dogs. J Surg Oncol 1971;3:163-168.
3.
Swales JD, Tange JD, Evans DJ: Intestinal ammonia in uraemia: the effect of a urease inhibitor, acetohydroxamic acid. Clin Sci 1972;42:105-112.
4.
Bourke E, Milne MD, Stokes GS: Caecal pH and ammonia in experimental uraemia. Gut 1966;7:558-561.
5.
Kang JY: The gastrointestinal tract in uremia. Dig Dis Sci 1993;38:257-268.
6.
Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK: Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985;80:608-611.
7.
Vaziri ND, Freel RW, Hatch M: Effect of chronic experimental renal insufficiency on urate metabolism. J Am Soc Nephrol 1995;6:1313-1317.
8.
Hatch M, Vaziri ND: Enhanced enteric excretion of urate in rats with chronic renal failure. Clin Sci 1994;86:511-516.
9.
Hatch M, Freel RW, Vaziri ND: Intestinal excretion of oxalate in chronic renal failure. J Am Soc Nephrol 1994;5:1339-1343.
10.
Aronov PA, Luo FJ, Plummer NS, et al: Colonic contribution to uremic solutes. J Am Soc Nephrol 2011;22:1769-1776.
11.
Meinardi S, Jin KB, Barletta B, Blake DR, Vaziri ND: Exhaled breath and fecal volatile organic biomarkers of chronic kidney disease. Biochim Biophys Acta 2013;1830:2531-2537.
12.
Niwa T: Uremic toxicity of indoxyl sulfate. Nagoya J Med Sci 2010;72:1-11.
13.
Smith EA, Macfarlane GT: Formation of phenolic and indolic compounds by anaerobic bacteria in the human large intestine. Microb Ecol 1997;33:180-188.
14.
Yokoyama MT, Carlson JR: Production of skatole and para-cresol by rumen Lactobacillus sp. Appl Environ Microbiol 1981;41:71-76.
15.
Ward LA, Johnson KA, Robinson IM, Yokoyama MT: Isolation from swine feces of a bacterium which decarboxylates p-hydroxyphenylacetic acid to 4-methylphenol (p-cresol). Appl Environ Microbiol 1987;53:189-192.
16.
Selmer T, Andrei PI: p-Hydroxyphenylacetate decarboxylase from Clostridium difficile: a novel glycyl radical enzyme catalyzing the formation of p-cresol. Eur J Biochem 2001;268:1363-1372.
17.
McDonald D, Price MN, Goodrich J, et al: An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J 2012;6:610-618.
18.
Levett PN, Phillips KD: Gas chromatographic identification of Clostridium difficile and detection of cytotoxin from a modified selective medium. J Clin Pathol 1985;38:82-85.
19.
Berg JD, Mills RG, Coleman DJ: Improved gas-liquid chromatography method for the identification of Clostridium difficile. J Clin Pathol 1985;38:108-113.
20.
Dawson LF, Donahue EH, Cartman ST, et al: The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. BMC Microbiol 2011;11:86.
21.
Vaziri ND, Yuan J, Norris K: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013;37:1-6.
22.
Vaziri ND, Yuan J, Khazaeli M, Masuda Y, Ichii H, Liu S: Oral activated charcoal adsorbent (AST-120) ameliorates chronic kidney disease-induced intestinal epithelial barrier disruption. Am J Nephrol 2013;37:518-525.
23.
Vaziri ND: CKD impairs barrier function and alters microbial flora of the intestine - a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012;21:587-592.
24.
Feroze U, Kalantar-Zadeh K, Sterling KA, et al: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012;22:317-326.
25.
Gonçalves S, Pecoits-Filho R, Perreto S, et al: Associations between renal function, volume status and endotoxaemia in chronic kidney disease patients. Nephrol Dial Transplant 2006;21:2788-2794.
26.
Szeto CC, Kwan BC, Chow KM, et al: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3:431-436.
27.
Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008;111:S4-S9.
28.
Stenvinkel P: Inflammation in end-stage renal disease: the hidden enemy. Nephrology (Carlton) 2006;11:36-41.
29.
Ruiz S, Pergola PE, Zager RA, Vaziri ND: Targeting Nrf2 activation to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int 2013;83:1029-1041.
30.
Vaziri ND, Yuan J, Rahimi A, Ni Z, Said H, Subramanian VS: Disintegration of colonic epithelial tight junction in uremia: a likely cause of CKD-associated inflammation. Nephrol Dial Transplant 2012;27:2686-2693.
31.
Vaziri ND, Yuan J, Nazertehrani S, Ni Z, Liu S: Chronic kidney disease causes disruption of gastric and small intestinal epithelial tight junction. Am J Nephrol 2013;38:99-103.
32.
Fierer N, Jackson RB: The diversity and biogeography of soil bacterial communities. Proc Natl Acad Sci 2006;103:626-631.
33.
Wakelin SA, Macdonald LM, Rogers SL, Gregg AL, Bolger TP, Baldock JA: Habitat selective factors influencing the structural composition and functional capacity of microbial communities in agricultural soils. Soil Biol Biochem 2008;40:803-813.
34.
Nacke H, Thurmer A, Wollherr A, et al: Pyrosequencing-based assessment of bacterial community structure along different management types in German forest and grassland soils. PLoS One 2011;6:e17000.
35.
Brown CL, Hill MJ, Richards P: Bacterial ureases in uraemic men. Lancet 1971;298:406-408.
36.
Lee HJ, Pahl MV, Vaziri ND, Blake DR: Effect of hemodialysis and diet on the exhaled breath methanol concentration in patients with ESRD. J Ren Nutr 2012;22:357-364.
37.
Donohoe DR, Garge N, Zhang X, et al: The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 2011;13:517-526.
38.
Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R: Diversity, stability and resilience of the human gut microbiota. Nature 2012;489:220-230.
39.
Vaziri ND, Pahl MV, Crum A, Norris K: Effect of uremia on structure and function of immune system. J Ren Nutr 2012;22:149-156.
40.
Hendrikx TK, van Gurp EA, Mol WM, et al: End-stage renal failure and regulatory activities of CD4+CD25bright+FoxP3+ T-cells. Nephrol Dial Transplant 2009;24:1969-1978.
41.
Smith PM, Howitt MR, Panikov N, et al: The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 2013;341:569-573.
42.
Krishnamurthy VMR, Wei G, Baird BC, et al: High dietary fiber intake is associated with decreased inflammation and all-cause mortality in patients with chronic kidney disease. Kidney Int 2012;81:300-306.
43.
Niwa T: Phenol and p-cresol accumulated in uremic serum measured by HPLC with fluorescence detection. Clin Chem 1993;39:108-111.
44.
Wikoff WR, Anfora AT, Liu J, et al: Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci 2009;106:3698-3703.
45.
Smith EA, Macfarlane GT: Enumeration of human colonic bacteria producing phenolic and indolic compounds: effects of pH, carbohydrate availability and retention time on dissimilatory aromatic amino acid metabolism. J Appl Bacteriol 1996;81:288-302.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.